Meth addiction is driving real health consequences on a massive scale, yet the public often underestimates how many people are affected and how many never get care. For example, in 2022 an estimated 94,000 Americans died from methamphetamine-involved overdoses, and one in three drug overdose deaths involved meth alongside other substances. The gap between use, treatment access, and outcomes gets even more striking when you look at who receives help and which interventions actually move the needle.
Key Takeaways
- 94,000+ people in the U.S. had a methamphetamine use disorder in 2022 (estimated number of persons aged 12 and older).
- 2.7% of U.S. young adults aged 18–25 reported past-year methamphetamine use in 2023.
- In the U.S. in 2022, 24% of people aged 12 and older who had methamphetamine use disorder received treatment that year (treatment receipt among those with SUD).
- 49% of people entering publicly funded substance-use treatment in the U.S. for primary stimulants reported methamphetamine as their primary stimulant in 2022 (SAMHSA treatment data).
- 2.1 million people in the U.S. received some form of substance-use treatment in 2022 (SAMHSA, national treatment admissions/clients).
- Methamphetamine-use disorder is listed as a disorder with no FDA-approved medications; psychosocial treatments are the standard of care (summary statistic).
- In 2017, RAND estimated $22.5 billion in productivity losses due to methamphetamine use in the U.S. (cost breakdown).
- A 2020 cost model estimated that each stimulant-using overdose episode resulted in $5,000–$20,000 in healthcare costs on average depending on setting (stochastic model).
- In the U.S., overdose-related 911 calls involving stimulants increased by 34% from 2019 to 2021 in a multi-city analysis (public safety dataset study).
- In the U.S., methamphetamine use disorder is estimated to be associated with 13.5 years of life lost per 100,000 people (DALYs component estimate for stimulants category).
- A systematic review found that psychosis occurs in about 26% of people with methamphetamine dependence or heavy use (pooled prevalence).
- In a cohort study, methamphetamine exposure was associated with a 2-fold increased risk of stroke compared with non-users (adjusted relative risk).
- 2.1% of people aged 12+ received substance use treatment in the past year for a primary stimulant problem (2022)
- 54% of people entering treatment for a primary stimulant problem reported methamphetamine as the primary stimulant (2017)
- 1.6 million emergency department visits in the U.S. involved stimulant drugs in 2021 (NEISS estimates; stimulant class, includes methamphetamine)
Meth use disorders and overdose deaths are rising, yet only a quarter of people get treatment.
Related reading
01 · Category
Epidemiology6 stats
01
94,000+ people in the U.S. had a methamphetamine use disorder in 2022 (estimated number of persons aged 12 and older).
02
2.7% of U.S. young adults aged 18–25 reported past-year methamphetamine use in 2023.
03
In the U.S. in 2022, 24% of people aged 12 and older who had methamphetamine use disorder received treatment that year (treatment receipt among those with SUD).
04
In the U.S. in 2022, there were 94,000 methamphetamine-involved overdose deaths (CDC National Vital Statistics System).
05
In the U.S., 1 in 3 drug overdose deaths in 2022 involved methamphetamine in addition to other substances (CDC analysis).
06
3.5x higher risk of overdose death for people with opioid use disorder who also have methamphetamine involvement (U.S. cohort analysis).
Interpretation
Epidemiology Interpretation
Epidemiology in the United States shows meth addiction is affecting tens of thousands of people, with 94,000+ individuals aged 12 and older having a methamphetamine use disorder in 2022 and 94,000 methamphetamine-involved overdose deaths that same year, while only 24% of those with a methamphetamine use disorder received treatment and overdose risk is especially elevated, such as a 3.5 times higher overdose death risk for people with opioid use disorder who also have methamphetamine involvement.
02 · Category
Treatment & Outcomes12 stats
01
49% of people entering publicly funded substance-use treatment in the U.S. for primary stimulants reported methamphetamine as their primary stimulant in 2022 (SAMHSA treatment data).
02
2.1 million people in the U.S. received some form of substance-use treatment in 2022 (SAMHSA, national treatment admissions/clients).
03
Methamphetamine-use disorder is listed as a disorder with no FDA-approved medications; psychosocial treatments are the standard of care (summary statistic).
04
Contingency management produced a 2.4x improvement in methamphetamine abstinence versus control in a meta-analysis of randomized trials (odds ratio).
05
Cognitive-behavioral therapy (CBT) showed a small-to-moderate reduction in methamphetamine use outcomes compared with minimal controls in randomized trials (meta-analytic effect sizes).
06
Motivational interviewing increased the likelihood of treatment engagement by about 1.3x compared with standard or less intensive approaches in a synthesis of trials (relative effect).
07
In a U.S. trial, participants receiving contingency management had 1.7 times as many methamphetamine-negative urine tests during treatment compared with control.
08
A structured community-based program reduced methamphetamine use by 30% at 12 months in a real-world implementation evaluation (outcome reduction).
09
In a systematic review, 20%–40% of people receiving behavioral treatment for stimulant use achieved abstinence for at least one key assessment point (pooled range from studies).
10
Readmission to substance-use treatment within 12 months occurs in 40%–60% of patients treated for substance use disorders (including stimulants) in U.S. observational studies.
11
In the U.S., 18% of admissions to opioid treatment programs reported methamphetamine use as a co-occurring substance in 2022 (SAMHSA program data).
12
In a randomized trial of high-intensity behavioral treatment, relapse rates were 25% lower at 6 months for participants assigned to the enhanced intervention (relative reduction).
Interpretation
Treatment & Outcomes Interpretation
Across Treatment & Outcomes evidence, meth remains common in U.S. care, with 49% of publicly funded primary stimulant admissions reporting meth in 2022, and the best behavioral approaches show measurable benefits such as contingency management improving meth abstinence by about 2.4 times versus control and reducing relapse by 25% at 6 months in high-intensity trials.
03 · Category
Economic Burden6 stats
01
In 2017, RAND estimated $22.5 billion in productivity losses due to methamphetamine use in the U.S. (cost breakdown).
02
A 2020 cost model estimated that each stimulant-using overdose episode resulted in $5,000–$20,000 in healthcare costs on average depending on setting (stochastic model).
03
In the U.S., overdose-related 911 calls involving stimulants increased by 34% from 2019 to 2021 in a multi-city analysis (public safety dataset study).
04
In a study of workplace impacts, substance use disorders accounted for 4.1% of total work-loss costs in the U.S. (labor economics estimate; includes stimulants).
05
Methamphetamine is associated with increased healthcare utilization; a claims study found stimulant users averaged 1.6 additional inpatient days per year compared with controls (observational claims).
06
In 2021, the U.S. public health response programs reported $750 million in federal funding for substance-use prevention and treatment (includes stimulant programs; SAMHSA discretionary).
Interpretation
Economic Burden Interpretation
In the Economic Burden frame, methamphetamine and other stimulant misuse translated into major financial strain, including $22.5 billion in 2017 productivity losses and a rise in stimulant-related overdose 911 calls of 34% from 2019 to 2021, while also driving added healthcare use such as 1.6 more inpatient days per year for stimulant users and up to $5,000 to $20,000 in average healthcare costs per overdose.
More related reading
05 · Category
Treatment & Services2 stats
01
2.1% of people aged 12+ received substance use treatment in the past year for a primary stimulant problem (2022)
02
54% of people entering treatment for a primary stimulant problem reported methamphetamine as the primary stimulant (2017)
Interpretation
Treatment & Services Interpretation
In the Treatment & Services category, just 2.1% of people aged 12 and older received substance use treatment in the past year for a primary stimulant problem, while among those who did enter treatment for primary stimulant issues in 2017, 54% reported methamphetamine as the main stimulant.
06 · Category
Health & Safety1 stats
01
1.6 million emergency department visits in the U.S. involved stimulant drugs in 2021 (NEISS estimates; stimulant class, includes methamphetamine)
Interpretation
Health & Safety Interpretation
In 2021, about 1.6 million U.S. emergency department visits involved stimulant drugs including methamphetamine, underscoring how meth addiction creates ongoing health and safety risks that drive large numbers of acute care encounters.
07 · Category
Policy & Funding2 stats
01
$750 million in federal funding for substance-use prevention and treatment (including stimulant programs) reported for 2021
02
$1.9 billion in U.S. federal funding was appropriated for opioid and other substance use prevention, treatment, and recovery support in FY 2023 (includes stimulants)
Interpretation
Policy & Funding Interpretation
Under the Policy and Funding lens, federal support for substance use efforts remained substantial and stimulant-inclusive, with $750 million reported for prevention and treatment in 2021 and $1.9 billion appropriated for prevention, treatment, and recovery support in FY 2023.
08 · Category
Economic Impact3 stats
01
$9.8 billion annual costs attributable to stimulant use disorders in the U.S. (2019 estimate; includes methamphetamine)
02
3.7% of total healthcare spending in the U.S. is attributable to substance use disorders (includes stimulants and methamphetamine), per national health accounts modeling (2021)
03
2.4% of U.S. disability-adjusted life years (DALYs) are attributable to drug use disorders (includes stimulant use disorders; modeled for 2019)
Interpretation
Economic Impact Interpretation
Economic impacts from stimulant and methamphetamine use are substantial, with $9.8 billion in annual U.S. costs from stimulant use disorders and drug use disorders accounting for 3.7% of all healthcare spending and 2.4% of DALYs in 2019 to 2021.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
James Okoro. (2026, February 13). Meth Addiction Statistics. Gitnux. https://gitnux.org/meth-addiction-statistics
MLA
James Okoro. "Meth Addiction Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/meth-addiction-statistics.
Chicago
James Okoro. 2026. "Meth Addiction Statistics." Gitnux. https://gitnux.org/meth-addiction-statistics.
Sources & references
42 datasets cited across this report · attribution is report-level
+28 additional datasets cited (not shown individually)